Jean M. Franchi's Insider Trades & SAST Disclosures
Jean M. Franchi's most recent trade in Disc Medicine Inc was a trade of 3,136 Common Stock done at an average price of $54.6 . Disclosure was reported to the exchange on Feb. 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jean M. Franchi.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Disc Medicine Inc | Jean M. Franchi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 54.58 per share. | 18 Feb 2025 | 3,136 | 69,530 | - | 54.6 | 171,163 | Common Stock |
| Disc Medicine Inc | Jean M. Franchi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 36,000 | 72,666 | - | 0 | Common Stock | |
| Disc Medicine Inc | Jean M. Franchi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Biodesix Inc | Jean M. Franchi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 60,766 | 60,766 | - | - | Restricted Stock Units | |
| Biodesix Inc | Jean M. Franchi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 37,050 | 37,050 | - | - | Stock Options (Right to Buy) | |
| Disc Medicine Inc | M. Franchi Jean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Disc Medicine Inc | Jean Franchi M. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 36,666 | 36,666 | - | 0 | Common Stock | |
| Biodesix Inc | M. Jean Franchi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 105,389 | 145,811 | - | - | Restricted Stock Units | |
| Biodesix Inc | Jean M. Franchi | Director | Grant, award, or other acquisition of securities at price $ 1.62 per share. | 03 Aug 2023 | 61,728 | 81,772 | - | 1.6 | 99,999 | Common Stock |
| Biodesix Inc | Jean M. Franchi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 40,422 | 40,422 | - | - | Restricted Stock Units | |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 16 May 2023 | 11,351 | 128,748 (0%) | 0% | 18.1 | 204,886 | Common Stock |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 67,500 | 67,500 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 45,000 | 140,099 (0%) | 0% | 0 | Common Stock | |
| Biodesix Inc | Jean M. Franchi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 7,317 | 153,150 | - | - | Restricted Stock Units | |
| Biodesix Inc | Jean M. Franchi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 62,500 | 145,833 | - | - | Restricted Stock Units | |
| Biodesix Inc | Jean M. Franchi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 83,333 | 83,333 | - | - | Restricted Stock Units | |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.59 per share. | 16 May 2022 | 3,436 | 95,099 (0%) | 0% | 14.6 | 50,131 | Common Stock |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 78,750 | 78,750 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 52,500 | 98,535 (0%) | 0% | 0 | Common Stock | |
| Biodesix Inc | Jean M. Franchi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 20,044 | 20,044 | - | - | Common Stock | |
| Biodesix Inc | Jean M. Franchi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 20,044 | 0 | - | - | Restricted Stock Units | |
| Biodesix Inc | Jean M. Franchi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 20,044 | 20,044 | - | - | Restricted Stock Units | |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 69,050 | 69,050 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 46,035 | 46,035 (0%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 14,900 | 140,000 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.08 per share. | 13 Jan 2021 | 14,900 | 14,900 (0%) | 0% | 14.1 | 209,792 | Common Stock |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 44.55 per share. | 13 Jan 2021 | 14,300 | 600 (0%) | 0% | 44.6 | 637,065 | Common Stock |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 44.00 per share. | 13 Jan 2021 | 600 | 0 (0%) | 0% | 44 | 26,400 | Common Stock |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 44.19 per share. | 13 Jan 2021 | 100 | 0 (0%) | 0% | 44.2 | 4,419 | Common Stock |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 100 | 154,900 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Jean M. Franchi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.08 per share. | 13 Jan 2021 | 100 | 100 (0%) | 0% | 14.1 | 1,408 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges